Shaanxi Province Unveils Ambitious Three-Year Plan to Boost Traditional Chinese Medicine Industry
The provincial government of Shaanxi has unveiled the “Three Year Action Plan for Empowering Shaanxi...
AstraZeneca’s Enhertu Receives Priority Review for Expanded HER2-positive Solid Tumor Indication
UK pharmaceutical company AstraZeneca (AZ; NASDAQ: AZN) has announced that an indication extension filing for...
MicroPort Scientific Corp. Forecasts 31%-34% Revenue Growth for Subsidiary MicroPort Endovascular in 2023
Shanghai-based medical device conglomerate MicroPort Scientific Corp., (HKG: 0853) has issued a revenue and growth...
SANDT Secures Nearly RMB 200 Million to Boost X-ray System Development and Manufacturing
SANDT, a Shanghai-based specialist in X-ray systems, has reportedly secured nearly RMB 200 million (USD...
Joincare Pharmaceutical Group Secures USD 100 Million Loan from IFC for Expansion
Joincare Pharmaceutical Group Industry Co., Ltd (SHA: 600380), a China-based pharmaceutical company, has announced securing...
South Korean Duo GC Wellbeing and YooYoung Pharmaceutical Target Chinese Filler Market
South Korean health and functional food manufacturer GC Wellbeing and YooYoung Pharmaceutical have formed a...
TYK Medicines Files for IPO on HKSE Amid Rising Losses and Expanding Drug Pipeline
Zhejiang-based TYK Medicines Inc. (HKG: 2410) has filed for an initial public offering (IPO) on...
Bristol Myers Squibb’s Subcutaneous Opdivo Shows Noninferiority in Phase III ccRCC Trial
Bristol Myers Squibb (BMS; NYSE: BMY) this week announced preliminary Phase III data demonstrating that...
Blue Sail Medical Secures RMB 900 Million Investment for R&D and Capacity Expansion
Blue Sail Medical Co., Ltd (SHE: 002382) has announced that its wholly owned subsidiary, Blue...
3D Medicines Partners with Sino Cellbiomed to Advance Tumor Immunotherapy Development
3D Medicines (HKG: 1244), a China-based oncology specialist, has entered into a partnership with Sino...
Mindray to Acquire 21.12% Stake in APT Medical for RMB 6.652 Billion
Mindray (SHE: 300760), a leading China-based medtech firm, has announced plans to acquire a 21.12%...
Johnson & Johnson’s Rybrevant and Lazertinib Filings Accepted for Review by CDE
The Center for Drug Evaluation (CDE) has confirmed that Johnson & Johnson’s (J&J, NYSE: JNJ)...
EMA’s CHMP Endorses Bristol Myers Squibb’s CAR-T Therapy Abecma for Multiple Myeloma
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)...
Dupixent by Sanofi and Regeneron Approved by FDA for Eosinophilic Esophagitis in Younger Pediatric Patients
The US Food and Drug Administration (FDA) has concluded a priority review and granted approval...
Shandong Boan Biotechnology Strikes Licensing Deal with Joincare for Long-Acting mAb BA2101
Shandong Boan Biotechnology Co., Ltd (HKG: 6955), based in China, has announced a licensing agreement...
Apeloa Pharmaceutical Halts Phase III Trial of Salfaprodil for Acute Ischemic Stroke
Apeloa Pharmaceutical Co., Ltd (SHE: 000739), a China-based pharmaceutical company, has announced the termination of...
Laekna Therapeutics Reports Phase II Data for Afuresertib in Platinum-Resistant Ovarian Cancer
Laekna Therapeutics Shanghai Co., Ltd, a China-based pharmaceutical company, has announced topline data from the...
Zhaoke Ophthalmology Strikes Distribution Deal with South Korea’s Kwangdong Pharmaceutical for Brimochol PF
Lee’s Pharmaceutical Holdings Ltd (HKG: 0950), a China-based pharmaceutical company, through its subsidiary Zhaoke Ophthalmology...
Yantai Dongcheng’s Radiopharmaceutical 68GaLNC1007 Gets FDA Nod for Diagnostic Use in Solid Tumors
Yantai Dongcheng Pharmaceutical Group Co., Ltd (SHE: 002675), a Chinese pharmaceutical company, has announced that...
Joincare Pharmaceutical Partners with QYuns Therapeutics for Exclusive Rights to QX008N in China and Hong Kong
Joincare Pharmaceutical Group Industry Co., Ltd (SHA: 600380), a Chinese pharmaceutical company, has announced a...